B-Cell Targeted Therapies in Systemic Sclerosis and Inflammatory Myopathies

Aggarwal, Rohit; Nagaraja, Vivek; Khanna, Dinesh

doi:10.1007/978-3-0348-0706-7_9

Cited by 2 publications

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B‐cells appear to play a key role in the initiation and propagation of the immune response [Aggarwal et al, ]. LPS has direct effects in B lymphocytes and promotes the full activation of mature B cells, giving rise to proliferation, and differentiation to plasmocytes [Vale et al, ].…”

Section: Discussionmentioning

confidence: 99%

Bone Marrow‐Derived Mesenchymal Stem Cells‐Mediated Protection Against Organ Dysfunction in Disseminated Intravascular Coagulation Is Associated With Peripheral Immune Responses

Wang

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

Disseminated intravascular coagulation (DIC) is a fatal thrombohemorrhagic disorder. Bone marrow-derived mesenchymal stem cells (BMSCs) are multipotent stem cells that have tremendous therapeutic effect. Our aim was to explore whether the immune mechanisms were associated with BMSCs-afforded protection against DIC. We generated a rat model of DIC by lipopolysaccharide (LPS, 3 mg/kg) injection via the tail vein. In the treatment group, rats were pre-treated with 1 × l0 , 1 × l0 , 1 × l0 , and 1 × l0 allogeneic BMSCs before LPS injection. Blood sample was withdrawn from the abdominal aorta at 0 (before), 4, and 8 h after LPS injection and used for biochemical analyses. After experiments, the mice were sacrificed and their organs were harvested and observed by H&E and PTAH staining. Continuous infusion of LPS into the rats gradually impaired the hemostatic parameters and damaged organ functions. However, pre-treatment with BMSCs dose-dependently improved the hemostatic parameters. Meanwhile, the treatment significantly suppressed the fibrin microthrombi formation and alleviated liver, heart, lung, and renal injuries. Flow cytometry analysis demonstrated that BMSCs pre-treatment inhibited LPS-induced upregulation of CD3 CD8 T cells and CD3 /CD161a NKT cells in the peripheral blood. BMSCs pre-treatment reversed the upregualtion of the B-cell population and the percentage of CD43 /CD172a monocytes in the DIC models. Finally, BMSCs pre-treatment decreased the levels of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), and interleukin-6 (IL-6) and increased the levels of interleukin-10 (IL-10) in LPS-induced DIC models. Pre-treatment with BMSCs can reduce coagulation and alleviate organ dysfunction via peripheral immune responses in LPS-induced DIC rat model. J. Cell. Biochem. 118: 3184-3192, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%